JSL
INFI

JT Stratford LLC’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

JT Stratford LLC’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,500
Closed -$20K – 239
2022
Q1 		$20K Buy
+17,500
New +$20.9K 0.01% 202

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

JT Stratford LLC's INFI Position: Q2 2022 in Review

JT Stratford LLC sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2022, closing a stake of 17,500 shares — an estimated $20K sold.

JT Stratford LLC first reported a position in INFI in Q1 2022 and held it in 1 quarter. The position peaked at $20K in Q1 2022. 77 funds tracked by Wall St. Rank hold INFI as of Q2 2022.

  • JT Stratford LLC reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • JT Stratford LLC sold 17,500 Infinity Pharmaceuticals, Inc. shares in Q2 2022, an estimated $20K.
  • JT Stratford LLC first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2022 and held it in 1 quarter.
  • JT Stratford LLC's Infinity Pharmaceuticals, Inc. position peaked at $20K in Q1 2022.
  • 77 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2022.

Based on JT Stratford LLC's 13F filing for Q2 2022, filed 15 Aug 2022.